RecruitingNot applicableNCT03725670
Direct Lentiviral Injection Gene Therapy for MLD
Studying Metachromatic leukodystrophy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Principal Investigator
- Lung-Ji Chang, Ph.DShenzhen Geno-Immune Medical Institute
- Intervention
- Intrathecal and intravenous LV gene therapy(genetic)
- Enrollment
- 10 enrolled
- Eligibility
- 50 years · All sexes
- Timeline
- 2025 – 2030
Study locations (1)
- Lung-Ji Chang, Shenzhen, Guangdong, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03725670 on ClinicalTrials.govOther trials for Metachromatic leukodystrophy
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07046338Lentiviral Hematopoietic Stem Cell Gene Therapy for MLDShenzhen Geno-Immune Medical Institute
- ACTIVE NOT RECRUITINGPHASE3NCT04283227OTL-200 in Patients With Late Juvenile Metachromatic Leukodystrophy (MLD)Orchard Therapeutics
- RECRUITINGNCT04925349Modeling Macrophages Activation Pattern in X-linked Adrenoleukodystrophy, Metachromatic Leukodystrophy and Adult Onset Leukoencephalopathy With Axonal Spheroids and Pigmented GliaAssistance Publique - Hôpitaux de Paris
- ACTIVE NOT RECRUITINGPHASE2NCT03771898A Study of Intrathecal SHP611 in Children With Metachromatic LeukodystrophyShire
- ACTIVE NOT RECRUITINGPHASE2NCT02171104MT2013-31: Allo HCT for Metabolic Disorders and Severe OsteopetrosisMasonic Cancer Center, University of Minnesota
- RECRUITINGNCT03333200Longitudinal Study of Neurodegenerative DisordersUniversity of Pittsburgh